TARIVID

This brand name is authorized in Estonia, Hong Kong SAR China, Ireland, Japan, Poland, Singapore, Turkey, UK.

Active ingredients

The drug TARIVID contains one active pharmaceutical ingredient (API):

1	Ofloxacin UNII A4P49JAZ9H - OFLOXACIN
	Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination.
	Read more about Ofloxacin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TARIVID Solution for infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01MA01	Ofloxacin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01M Quinolone antibacterials → J01MA Fluoroquinolones
Discover more medicines within J01MA01
S02AA16		S Sensory organs → S02 Otologicals → S02A Antiinfectives → S02AA Antiinfectives
Discover more medicines within S02AA16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1007637, 1070693, 1070705
GB	Medicines & Healthcare Products Regulatory Agency	111375, 44152
HK	Department of Health Drug Office	31348, 31349, 36357
IE	Health Products Regulatory Authority	49581
JP	医薬品医療機器総合機構	1319722M1056, 1319722Q1163, 1329706Q1039, 6241006F1121
PL	Rejestru Produktów Leczniczych	100065746
SG	Health Sciences Authority	06826P, 11261P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699809097506, 8699809097605